REG - Futura Medical PLC - Futura Medical Announces Investor Seminar

Futura MedicalAnnouncement

08/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH0215Ca&default-theme=true

RNS Number : 0215C  Futura Medical PLC  08 June 2023

 

 

8 June 2023

 

  Futura Medical plc

("Futura" or the "Company")

Futura Medical Announces Investor Seminar

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, is
pleased to announce that it will be hosting an Investor Seminar on the 22 June
2023 in London for analysts and institutional investors. Following the
Investor Seminar, an Investor Meet Company meeting will be held for Retail
Investors on Monday the 26 June.

 

The Investor Seminar follows a milestone year to date following the UK launch
on the 18 April 2023 of MED3000 under the brand name Eroxon® with Cooper
Consumer Health, its EU and UK distribution partner, and online launches in
Europe and in retail pharmacies in Belgium.

 

The Investor Sseminar will feature presentations from Futura as well as
eminent Key Opinion Leaders (KOLs) Dr Jeff Foster, BSc, (Hons), MB ChB, DRCOG,
MRCGP, men's health specialist and book author and Dr Janine David, FECSM, GP
who specialises in Men and Women's sexual health and will close with a
presentation by Mark Berkhout, International Marketing Director for Cooper
Consumer Health & Jon Connolly Marketing Director Ceuta Healthcare

 

For further information on the Investor Seminar, or to register your interest,
please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com. Further information will be made available
closer to the event.

 

A recording will be made available through a webcast which can be accessed via
the investor section of the Futura website shortly after the event. No new
material disclosures will be made at the event.

 

The Retail Investor event is scheduled for Monday 26 June at 10:00am with
Investor Meet Company. Retail Investors can sign up to Investor Meet Company
for free via www.investormeetcompany.com (http://www.investormeetcompany.com)
.

 

-ENDS-

 

For further information, please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.

 

Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon®, with a key claim of "Helps you get an erection
within 10 minutes". Eroxon® is the agreed brand name in certain regions such
as the EU whereas MED3000 continues to be the internal code name used by the
Company and also in reference

to countries where regulatory approval or commercial distribution agreements
have not yet been achieved. www.eroxon.com (http://www.eroxon.com) .

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFRMLTMTTMBAJ